Clinical Trial Update: Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial update of lenalidomide after salvage therapy in relapsed/refractory non-Hodgkin T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin T-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Samsung Medical Center | Conditions: Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma | Phase 2 | Status: UNKNOWN